SCHEMBL18310461

SCHEMBL18310461

C=CC1CCC(C2CCC(c3ccc(OCF)cc3)CC2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 12/20 0.34
KCNH2 Q12809 4/20 0.34
CYP3A4 P08684 4/20 0.34
CYP2C9 P11712 4/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
DRD5 P21918 1/20 0.33
HTR2A P28223 1/20 0.33
DRD3 P35462 1/20 0.33
RAB9A P51151 2/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18310393 0.95 HRH3 (0.36) HRH3KCNH2CYP3A4CYP2C9MRGPRX4
SCHEMBL18310443 0.91 HRH3 (0.34) HRH3KCNH2CYP3A4CYP2C9MRGPRX4
SCHEMBL19542829 0.89 HRH3 (0.38) HRH3KCNH2CYP3A4CYP2C9HTR1A
SCHEMBL19829158 0.89 FFAR4 (0.36) HRH3KCNH2CYP3A4CYP2C9MRGPRX4
SCHEMBL19542809 0.87 HRH3 (0.40) HRH3KCNH2CYP3A4CYP2C9HTR1A
SCHEMBL19850730 0.85 NQO1 (0.41) DRD2RAB9AMEN1NPC1KMT2A
SCHEMBL18310462 0.85 CYP3A4 (0.32) HRH3KCNH2CYP3A4CYP2C9HTR1A
SCHEMBL18310455 0.83 HRH3 (0.33) HRH3KCNH2CYP3A4CYP2C9MRGPRX4
SCHEMBL15180872 0.80 ESR2 (0.47) HRH3KCNH2CYP3A4CYP2C9MRGPRX4
SCHEMBL15274896 0.80 NQO1 (0.45) DRD2RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951277-B2 Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2018-04-24 US disclosed
US-20180030351-A1 LIQUID CRYSTAL COMPOUND HAVING POLYFLUORO-2-BUTENOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-02-01 US disclosed
US-20160362605-A1 LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362605-A1 LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE TCOF1, PIEZO1, RCC1 HRH3 680/4885KCNH2 1244/4885CYP3A4 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.